Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 205

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 205
---
 and rights to receive
a distribution of assets upon liquidation.

| During April, May, August and December 2023, the Company signed an investment agreement with certain investors for gross proceeds of $1,594, according to which the Company received net amount of $1,594 and issued 16,244 Ordinary shares NIS 0.1 par value. |

Successor:

On July 23, 2024, the Company issued to the former
Predecessor shareholders an aggregate of 23,171,642 restricted shares of the Company’s common stock, representing 40% of the outstanding
shares of the Company immediately following closing (see note 3).

<div align='center'>F-25</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

Predecessor

On August 10, 2023, the Predecessor adopted the
2023 Share Award Plan to directors, employees and service providers to purchase an aggregate of 23,000 shares of Ordinary shares exercisable
through the tenth anniversary (10th) of date of the issuance.

On November 15, 2023, the Predecessor granted
5,657 options to purchase Company’s 5,657 Ordinary Shares to Company’s Chief Technology Officer. 1,415 options vested on date of grant,
1,414 options will vest on April 10, 2024, 1,414 options will vest on October 10, 2024, and 1,414 options on April 10, 2025. The exercise
price is $100 per share, and the options expire on November 15, 2033.

The aggregate grant date fair value of such options
was $531. The fair value of the Company’s share options granted was estimated using the black Scholes model with the following assumptions:

| Description                 |     | 2023 grants |       |   |
| Risk-free interest rate     |     |             |  4.25 | % |
| Expected volatility         |     |             | 115.5 | % |
| Dividend yield              |     |             |     0 | % |
| Contractual life (in years) |     |             |    10 |   |

On March 18, 2024, the Predecessor granted
3,000